These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17512448)

  • 1. Chemotherapy for metastatic breast cancer.
    Mayer EL; Burstein HJ
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):257-72. PubMed ID: 17512448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy in breast cancer.
    Lake DE; Hudis CA
    Drugs; 2004; 64(17):1851-60. PubMed ID: 15329034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of chemotherapy in metastatic breast cancer.
    Garber JE; Henderson IC
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):807-21. PubMed ID: 2481671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
    Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy for early-stage breast cancer.
    McArthur HL; Hudis CA
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Glasgow Prognostic Score Predicts Response to Chemotherapy in Patients with Metastatic Breast Cancer.
    Wang D; Duan L; Tu Z; Yan F; Zhang C; Li X; Cao Y; Wen H
    Chemotherapy; 2016; 61(4):217-22. PubMed ID: 26905743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
    Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs in metastatic breast cancer: an update.
    Arslan C; Altundag K; Dizdar O
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):647-67. PubMed ID: 22122529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting metastatic and advanced breast cancer.
    Moore S; Cobleigh MA
    Semin Oncol Nurs; 2007 Feb; 23(1):37-45. PubMed ID: 17303515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Usefulness of antimycotic agents (itraconazole) in chemotherapy-induced mucositis of breast cancer patients].
    Tsuyuki S; Kawaguchi K; Kawata Y; Yamaguchi A; Kanazawa A; Sugitatsu M; Kono Y
    Gan To Kagaku Ryoho; 2012 Sep; 39(9):1369-73. PubMed ID: 22996771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
    Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
    Shigekawa T; Osaki A; Sekine H; Sato N; Kanbayashi C; Sano H; Takeuchi H; Ueda S; Nakamiya N; Sugitani I; Sugiyama M; Shimada H; Hirokawa E; Takahashi T; Saeki T
    BMC Cancer; 2015 Apr; 15():253. PubMed ID: 25884795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
    Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.